Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Opioid-Induced Constipation (OIC)-Pipeline Review, H1 2015

Opioid-Induced Constipation (OIC)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Opioid-Induced Constipation (OIC)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Opioid-Induced Constipation (OIC)-Pipeline Review, H1 2015', provides an overview of the Opioid-Induced Constipation (OIC)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Opioid-Induced Constipation (OIC) Overview 7

Therapeutics Development 8

Pipeline Products for Opioid-Induced Constipation (OIC)-Overview 8

Pipeline Products for Opioid-Induced Constipation (OIC)-Comparative Analysis 9

Opioid-Induced Constipation (OIC)-Therapeutics under Development by Companies 10

Opioid-Induced Constipation (OIC)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Opioid-Induced Constipation (OIC)-Products under Development by Companies 14

Opioid-Induced Constipation (OIC)-Companies Involved in Therapeutics Development 15

AstraZeneca PLC 15

Cosmo Pharmaceuticals S.p.A 16

Cubist Pharmaceuticals, Inc. 17

Develco Pharma Schweiz AG 18

Ironwood Pharmaceuticals, Inc. 19

S.L.A. Pharma AG 20

Salix Pharmaceuticals Ltd. 21

Shionogi & Co., Ltd. 22

Sucampo Pharmaceuticals, Inc. 23

Synergy Pharmaceuticals, Inc. 24

Opioid-Induced Constipation (OIC)-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

axelopran-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

bevenopran-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

linaclotide-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

lubiprostone-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

methylnaltrexone bromide-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

naldemedine-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

naloxegol oxalate-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

naloxone hydrochloride-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

naloxone hydrochloride PR-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

naloxone hydrochloride SR-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

SP-333-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Opioid-Induced Constipation (OIC)-Recent Pipeline Updates 53

Opioid-Induced Constipation (OIC)-Dormant Projects 72

Opioid-Induced Constipation (OIC)-Discontinued Products 73

Opioid-Induced Constipation (OIC)-Product Development Milestones 74

Featured News & Press Releases 74

Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Canada 74

Dec 09, 2014: MOVENTIG approved in the European Union for opioid-induced constipation 74

Nov 19, 2014: Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation 75

Oct 16, 2014: Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation 76

Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting 77

Oct 06, 2014: Progenics Receives $40 Million Milestone Following FDA Approval of RELISTOR for OIC Patients With Chronic Non-Cancer Pain 77

Sep 29, 2014: Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA (lubiprostone) for Chronic Idiopathic Constipation 78

Sep 29, 2014: FDA Approves RELISTOR Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain 79

Sep 26, 2014: MOVENTIG (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation 80

Sep 16, 2014: FDA Approves MOVANTIK (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain 81

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 83

Disclaimer 83

List of Tables

Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2015 8

Number of Products under Development for Opioid-Induced Constipation (OIC)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Opioid-Induced Constipation (OIC)-Pipeline by AstraZeneca PLC, H1 2015 15

Opioid-Induced Constipation (OIC)-Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 16

Opioid-Induced Constipation (OIC)-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 17

Opioid-Induced Constipation (OIC)-Pipeline by Develco Pharma Schweiz AG, H1 2015 18

Opioid-Induced Constipation (OIC)-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 19

Opioid-Induced Constipation (OIC)-Pipeline by S.L.A. Pharma AG, H1 2015 20

Opioid-Induced Constipation (OIC)-Pipeline by Salix Pharmaceuticals Ltd., H1 2015 21

Opioid-Induced Constipation (OIC)-Pipeline by Shionogi & Co., Ltd., H1 2015 22

Opioid-Induced Constipation (OIC)-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 23

Opioid-Induced Constipation (OIC)-Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 33

Opioid-Induced Constipation (OIC) Therapeutics-Recent Pipeline Updates, H1 2015 53

Opioid-Induced Constipation (OIC)-Dormant Projects, H1 2015 72

Opioid-Induced Constipation (OIC)-Discontinued Products, H1 2015 73

List of Figures

Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2015 8

Number of Products under Development for Opioid-Induced Constipation (OIC)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca PLC

Cosmo Pharmaceuticals S.p.A

Cubist Pharmaceuticals, Inc.

Develco Pharma Schweiz AG

Ironwood Pharmaceuticals, Inc.

S.L.A. Pharma AG

Salix Pharmaceuticals Ltd.

Shionogi & Co., Ltd.

Sucampo Pharmaceuticals, Inc.

Synergy Pharmaceuticals, Inc.

Opioid-Induced Constipation (OIC) Therapeutic Products under Development, Key Players in Opioid-Induced Constipation (OIC) Therapeutics, Opioid-Induced Constipation (OIC) Pipeline Overview, Opioid-Induced Constipation (OIC) Pipeline, Opioid-Induced Constipation (OIC) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com